<scp>NeuroSAFE</scp> in radical prostatectomy increases the rate of nerve‐sparing surgery without affecting oncological outcome
Margaretha A. van der Slot, Michael A. den Bakker, Tamara S. C. Tan, Sebastiaan Remmers, Martijn B. Busstra, M. Gan, Sjoerd Klaver, John Rietbergen, Charlotte F. Kweldam, Mike Kliffen, K.E. Hamoen, Leo M. Budel, Natascha Goemaere, Jozien Helleman, Chris H. Bangma, Monique J. Roobol, Geert J.L.H. van Leenders
- Year
- 2022
- Citations
- 40
- Access
- Open access
Abstract
OBJECTIVES: To investigate the impact of intra-operative neurovascular structure-adjacent frozen-section examination (NeuroSAFE) on the rate of nerve-sparing surgery (NSS) and oncological outcome in a large radical prostatectomy (RP) cohort. PATIENTS AND METHODS: Between January 2016 and December 2020, 1756 prostate cancer patients underwent robot-assisted RP, of whom 959 (55%) underwent this with NeuroSAFE and 797 (45%) without (control cohort). In cases where NeuroSAFE showed tumour in the margin, a secondary resection was performed. The effect of NeuroSAFE on NSS and positive surgical margin (PSM) status was analysed using logistic regression. Cox regression was used to identify predictors of biochemical recurrence-free survival (BCRFS). RESULTS AND LIMITATIONS: Patients in the NeuroSAFE cohort had a higher tumour grade (P < 0.001) and clinical stage (P < 0.001) than those in the control cohort. NeuroSAFE enabled more frequent NSS for both pT2 (93% vs 76%; P < 0.001) and pT3 disease (83% vs 55%; P < 0.001). In adjusted analysis, NeuroSAFE resulted in more frequent unilateral (odds ratio [OR] 3.90, 95% confidence interval (CI) 2.90-5.30; P < 0.001) and bilateral (OR 5.22, 95% CI 3.90-6.98; P < 0.001) NSS. While the PSM rate decreased from 51% to 42% in patients with pT3 stage disease (P = 0.031), NeuroSAFE was not an independent predictor of PSM status (OR 0.85, 95% CI 0.68-1.06; P = 0.2) in the entire cohort. Patients who underwent NeuroSAFE had better BCRFS compared to the control cohort (hazard ratio 0.62, 95% CI 0.45-0.84; P = 0.002). This study is limited by its comparison with a historical cohort and lack of functional outcomes. CONCLUSIONS: NeuroSAFE enables more unilateral and bilateral NSS without negatively affecting surgical margin status and biochemical recurrence. This validation study provides a comprehensive overview of the implementation, evaluation and intra-operative decision making associated with NeuroSAFE in clinical practice.
Keywords
Related papers
Robots and Jobs: Evidence from US Labor Markets
Daron Acemoğlu, Pascual Restrepo
2019
Reach and grasp by people with tetraplegia using a neurally controlled robotic arm
Leigh R. Hochberg, Daniel Bacher, Beata Jarosiewicz +8 more
2012
Campbell-Walsh urology
Alan J. Wein editor-in-chief
2012
Stroke rehabilitation
Peter Langhorne, Julie Bernhardt, Gert Kwakkel
2011